NovaBridge Biosciences

NBP

Biotechnology · Healthcare

Exchange

NASDAQ

Winston Score

–

No score yet — Winston is napping.

We couldn’t gather enough financial data to score this stock reliably.

Track this stock — start free trial

Winston Score History

The full picture

NovaBridge Biosciences is a small biotechnology company focused on developing new medicines, most likely in early-stage clinical research. Like many small biotech firms, it does not yet sell commercial products, meaning it has no revenue from drug sales. Its work is aimed at discovering and testing experimental therapies, typically for diseases with limited treatment options.

The company's financials reflect a pre-revenue stage: a gross margin of zero and a deeply negative return on invested capital of nearly -95% show that it is spending heavily on research while earning nothing yet. Small biotechs like NovaBridge typically fund operations through stock offerings, grants, or partnerships with larger pharmaceutical companies. Operating at this scale, the company faces the core risk that all early-stage biotechs share — clinical trials can fail, and without successful trial results or a partnership deal, cash can run out before any drug reaches the market.

Growth Profile

For growth stock investors

When traditional metrics don't capture the full picture, these are the signals growth stock investors use instead.

Revenue Growth

YoY Growth Rate

Revenue data limited

EPS Growth

+19.3% YoY

YoY Growth Rate

Steady EPS growth

Insider Activity

16.2%ownership

→ Flat

Insider ownership roughly steady over the past year

Cash Runway

~7 months

$35M cash & investments

Short runway — potential dilution ahead through share issuance

Cash watch

NovaBridge Biosciences has less than a year of cash at its current burn rate. Growth investors should watch for potential share dilution from future fundraising — that directly reduces your ownership.

The Winston Score above measures business quality today. Growth stocks often score lower because they invest in the future rather than maximising current profits. These metrics show what matters most for evaluating that future.

Score breakdown

Every number that matters to educated investors.

Each metric is explained in plain language so you know exactly what you're looking at. Start your free trial now.

Quality

Profit per sale

Gross Margin

N/A

Data not available

Profit after running costs

Operating Margin

N/A

Data not available

Return on the money invested

ROCE

-96.3%

Weak — -96.3% return on capital

Negative ROIC means the business is losing money on every dollar invested in it.

Full breakdown available with your free trial

See every metric, trend, and what it means for this stock.

Try free

Growth

Sales growth

Sales YoY

-100.0%

Shrinking sales (-100.0% YoY)

Profit growth

EPS YoY

N/A

Data not available

How steady the profit is

EPS Consistency

6/8 quarters

Earnings grew in most of the last 8 quarters

Full breakdown available with your free trial

See every metric, trend, and what it means for this stock.

Try free

Cash Flow

Profit that turns into cash

Cash Conversion

N/A

Data not available

Spare cash per sale

FCF Margin

N/A

Data not available

Full breakdown available with your free trial

See every metric, trend, and what it means for this stock.

Try free

Stability

What it owes vs what it owns

Debt / Equity

N/A

Data not available

Covers its interest

Interest Cover

N/A

—

Data not available

Full breakdown available with your free trial

See every metric, trend, and what it means for this stock.

Try free

Valuation

Price vs profit

P/E Ratio (TTM)

N/M

no trend

Negative earnings — P/E not meaningful

Cheaper or dearer next year

P/E vs Forward

N/A

not available

Data not available

Full breakdown available with your free trial

See every metric, trend, and what it means for this stock.

Try free

Dividends

Not applicable for this business.

🔒 See full fundamentals and if they are improving or declining — click here for your free trial now.

Start free trial